Last reviewed · How we verify
HyperRAB
HyperRAB is a rabies immunoglobulin (human) that provides passive immunity by supplying antibodies against rabies virus.
HyperRAB is a rabies immunoglobulin (human) that provides passive immunity by supplying antibodies against rabies virus. Used for Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies exposure.
At a glance
| Generic name | HyperRAB |
|---|---|
| Also known as | HRIG |
| Sponsor | Bio Products Laboratory |
| Drug class | Rabies immunoglobulin (human) |
| Target | Rabies virus glycoprotein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
HyperRAB contains human rabies antibodies that neutralize rabies virus and prevent its spread to the central nervous system. It is administered as part of post-exposure prophylaxis (PEP) following potential rabies exposure, working in conjunction with rabies vaccine to provide immediate protection while the immune system develops active immunity.
Approved indications
- Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies exposure
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Survey of Human Rabies Immune Globulin Safety in Children
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyperRAB CI brief — competitive landscape report
- HyperRAB updates RSS · CI watch RSS
- Bio Products Laboratory portfolio CI